The objective of this prospective meta-analysis recently published in JAMA was to estimate the association between administration of corticosteroids compared with usual care or placebo and 28-day all-cause mortality. The prospective meta-analysis pooled data from 7 randomised trials that included 1703 patients, of whom 647 died. The authors found that the 28-day all-cause mortality was lower among patients who received corticosteroids compared with those who received usual care or placebo (summary odds ratio, 0.66). The authors concluded that, in this prospective meta-analysis of clinical trials of critically ill patients with COVID-19, administration of systemic corticosteroids, compared with usual care or placebo, was associated with lower 28-day all-cause mortality.